| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Munir Pirmohamed | Q20127995 |
| P2093 | author name string | David Back | |
| Macpherson Mallewa | |||
| Dominic Doran | |||
| Javier Vilar | |||
| Edmund Wilkins | |||
| Jane E Mallewa | |||
| P2860 | cites work | Metformin: new understandings, new uses | Q22241434 |
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity | Q24532873 | ||
| Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients | Q44738362 | ||
| Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial | Q44975160 | ||
| Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species | Q44987425 | ||
| Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines | Q45138632 | ||
| Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial | Q45268076 | ||
| Leptin-replacement therapy for lipodystrophy. | Q45714149 | ||
| Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting | Q45730277 | ||
| Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients | Q46575884 | ||
| Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines | Q46675079 | ||
| Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone | Q46789882 | ||
| Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes | Q46812369 | ||
| GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study | Q46831264 | ||
| Thiazolidinediones and cardiovascular outcomes in older patients with diabetes | Q46855431 | ||
| Metabolic effects of a growth hormone-releasing factor in patients with HIV. | Q46867993 | ||
| Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects | Q46926316 | ||
| Antiatherothrombotic properties of statins: implications for cardiovascular event reduction | Q48011361 | ||
| NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. | Q50920620 | ||
| Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients. | Q51480420 | ||
| Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. | Q51499410 | ||
| Effectiveness of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy. | Q53198085 | ||
| Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 | Q28511676 | ||
| Disruption of adiponectin causes insulin resistance and neointimal formation | Q28589597 | ||
| C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus | Q29619398 | ||
| Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy | Q31831126 | ||
| Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis | Q33228326 | ||
| Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia | Q33946056 | ||
| RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin | Q34377294 | ||
| Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease | Q34384926 | ||
| NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction? | Q34459416 | ||
| Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens | Q34467040 | ||
| Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding | Q34490102 | ||
| Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients | Q34987957 | ||
| Monocyte chemoattractant protein 1 in obesity and insulin resistance | Q35163496 | ||
| Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha | Q35209149 | ||
| Regulation of adipocytokines and insulin resistance | Q35579025 | ||
| Obesity, adiponectin and vascular inflammatory disease | Q35587168 | ||
| Adiponectin: action, regulation and association to insulin sensitivity | Q36011919 | ||
| Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin | Q36051630 | ||
| Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity | Q36278045 | ||
| Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review | Q36396145 | ||
| Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. | Q36602451 | ||
| Monocyte chemoattractant protein-1--a major contributor to the inflammatory process associated with diabetes | Q36687948 | ||
| Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome | Q36724153 | ||
| Monocyte chemoattractant protein-1 and atherosclerosis: is there room for an additional biomarker? | Q36830400 | ||
| Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study | Q37097126 | ||
| Monocyte chemoattractant protein-1 in subcutaneous abdominal adipose tissue: characterization of interstitial concentration and regulation of gene expression by insulin | Q38302405 | ||
| European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. | Q40126108 | ||
| HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism | Q40252395 | ||
| Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy | Q40331192 | ||
| Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. | Q40448907 | ||
| Trends in diagnostic testing following a national guideline for evaluation of dyspepsia | Q41085074 | ||
| Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance | Q42684893 | ||
| Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes | Q42819615 | ||
| Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels | Q44522392 | ||
| Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice | Q44539517 | ||
| Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy | Q44618186 | ||
| Combination antiretroviral therapy and the risk of myocardial infarction | Q44662157 | ||
| Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients | Q44686551 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| HIV-associated lipodystrophy | Q5629813 | ||
| P304 | page(s) | 648-660 | |
| P577 | publication date | 2008-06-18 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options | |
| P478 | volume | 62 |
| Q37248700 | Adipocyte lineages: tracing back the origins of fat. |
| Q28481666 | Associations between HIV and human pathways revealed by protein-protein interactions and correlated gene expression profiles |
| Q38085854 | Autoinflammation: From monogenic syndromes to common skin diseases |
| Q40067147 | CANDLE Syndrome As a Paradigm of Proteasome-Related Autoinflammation |
| Q33665359 | Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? |
| Q92980318 | Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation: An observational cohort study |
| Q35063208 | Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy. |
| Q35018992 | Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy |
| Q35259915 | Current and Novel Inhibitors of HIV Protease |
| Q38438251 | Deciphering the molecular mechanisms involved in HIV-associated lipoatrophy by transcriptomics: a pilot study. |
| Q59356122 | Differential contribution of chronic binge alcohol and antiretroviral therapy to metabolic dysregulation in SIV-infected male macaques |
| Q56791508 | Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines |
| Q38155007 | Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies |
| Q37970040 | Gene array studies in HIV-1 infection |
| Q39881130 | HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone |
| Q28088839 | HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings |
| Q46177989 | Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression |
| Q37650120 | Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action |
| Q34058478 | LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART. |
| Q36068146 | Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART). |
| Q42228156 | Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin. |
| Q35148915 | Lipodystrophy: pathophysiology and advances in treatment |
| Q41206883 | Long Distance Metabolic Regulation through Adipose-Derived Circulating Exosomal miRNAs: A Trail for RNA-Based Therapies? |
| Q50132896 | Metabolic Effects of Pre-Exposure Prophylaxis with Co-Formulated Tenofovir Disoproxal Fumarate and Emtricitabine |
| Q35945312 | Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy |
| Q36952291 | Metabolic complications and treatment of perinatally HIV-infected children and adolescents |
| Q37776761 | Molecular mechanisms controlling human adipose tissue development: insights from monogenic lipodystrophies |
| Q41972161 | Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity. |
| Q35557229 | New and emerging agents in the management of lipodystrophy in HIV-infected patients |
| Q38061798 | Nutrition and the HIV-associated lipodystrophy syndrome |
| Q34113354 | Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin |
| Q40520851 | Placental leptin mRNA expression and serum leptin levels in pre-eclampsia associated with HIV infection |
| Q33600363 | Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART). |
| Q38393674 | Retroviral proteases and their roles in virion maturation |
| Q35834842 | Role of microRNA biogenesis in adipocyte and lipodystrophy |
| Q37645670 | Shortcuts to a functional adipose tissue: The role of small non-coding RNAs. |
| Q35754572 | The Molecular Signature of HIV-1-Associated Lipomatosis Reveals Differential Involvement of Brown and Beige/Brite Adipocyte Cell Lineages |
Search more.